Heparin News and Research

RSS

Heparin, a highly-sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines. Pharmaceutical grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestine or bovine (cow) lung.

GlaxoSmithKline acquires injectable anti-thrombotic agents Fraxiparine® and Arixtra®

GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.

13 Apr 2004

Forward step in treatment of Allergic Rhinitis

Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company’s lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.

22 Mar 2004